Evidence map›Paper›PMID 40634793›Full record

ArticleReproductive sciences (Thousand Oaks, Calif.)2025

Gonadotropin Releasing Hormone-Antagonist Protocol (GnRH-ant) Combined Letrozole (LE) for Expected High Ovarian Responders (HOR): a Cohort Study.

Wenxiao Feng, Min Zhou, Qiuying Li, Hui Chen, Jinyu Lu, Yang Sui

Abstract read
PubMed Publisher
In one paragraph

Article in Reproductive sciences (Thousand Oaks, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wenxiao FengChina Medical University, Liaoning Institute of Birth Health and developmentReproductive Hospital of China Medical UniversityLiaoNing Province, 10#Puhe Street Huanggu District, ShenYang City, China.ORCID 0000-0002-8769-277X
Min ZhouChina Medical University, Liaoning Institute of Birth Health and developmentReproductive Hospital of China Medical UniversityLiaoNing Province, 10#Puhe Street Huanggu District, ShenYang City, China.
Qiuying LiChina Medical University, Liaoning Institute of Birth Health and developmentReproductive Hospital of China Medical UniversityLiaoNing Province, 10#Puhe Street Huanggu District, ShenYang City, China.
Hui ChenChina Medical University, Liaoning Institute of Birth Health and developmentReproductive Hospital of China Medical UniversityLiaoNing Province, 10#Puhe Street Huanggu District, ShenYang City, China.
Jinyu LuChina Medical University, Liaoning Institute of Birth Health and developmentReproductive Hospital of China Medical UniversityLiaoNing Province, 10#Puhe Street Huanggu District, ShenYang City, China.
Yang SuiChina Medical University, Liaoning Institute of Birth Health and developmentReproductive Hospital of China Medical UniversityLiaoNing Province, 10#Puhe Street Huanggu District, ShenYang City, China. suiyang2014@163.com.ORCID 0000-0003-3903-661X

Funding

Natural Science Foundation of Liaoning Province 2019ZD0840
6 · The paper itself

Abstract

High ovarian responders are at high risk of developing ovarian hyperstimulation syndrome (OHSS) in in vitro fertilization (IVF). Letrozole administration during the gonadotropin period has the theoretical basis to avoid OHSS. But researches are just beginning. Our prospective cohort study was conducted to explore if the addition of LE are better or not. Totally 107 high responders who received IVF were included, 66 patients for GnRH-ant protocol and 41 patients for co-LE protocol with letrozole combination during gonadotropin period from day 1 to day 5. The IVF outcomes appeared: the clinical pregnancy rate, cumulative pregnancy rate, live birth and ongoing pregnancy rate were both comparable (p > 0.05). Patients in the co-LE group exhibited significantly less gonadotropin dose (1464.39 ± 550.84 vs. 1708.23 ± 455.75, p = 0.015), gonadotropin duration (9.63 ± 2.11 vs. 10.48 ± 1.83 days, p = 0.032) and oocytes number (13.29 ± 10.30 vs. 18.18 ± 9.36, p = 0.013). The incidence of early OHSS was significantly lower than that in the GnRH-ant group (0% & 13.6%, p = 0.025). According to our research, the combination of letrozole can improve controlled ovarian stimulation (COS) efficiency and reduce the risk of OHSS while bring effective IVF clinical outcomes equivalent to GnRH-ant regimen for ovarian hyperresponders.

Indexed as

Fertility Agents, FemaleFertilization in VitroGonadotropin-Releasing HormoneLetrozoleNitrilesOvulation InductionTriazolesAdultAromatase InhibitorsCohort StudiesDrug Therapy, CombinationFemaleHumansOvarian Hyperstimulation SyndromePregnancyPregnancy RateAromatase InhibitorsFertility Agents, FemaleGonadotropin-Releasing HormoneLetrozoleNitrilesTriazolesHigh ovarian responderIVFLetrozoleOHSS

Identifiers

PMID40634793

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.